博纳吐单抗治疗复发/难治性费城染色体阳性B前体急性淋巴细胞白血病成人患者后获得完全血液学和分子学缓解:一项II期、单臂、多中心研究结果
这项开放标签II期多中心单臂研究评估了博纳吐单抗在复发/难治性费城染色体阳性B前体急性淋巴细胞白血病成人患者中的疗效与耐受性。45例患者中16例(36%;95%CI 22%至51%)在前两个周期内达到完全缓解或部分血液学恢复的完全缓解,88%的缓解者达到完全微小残留病缓解。最常见不良事件为发热、发热性中性粒细胞减少和头痛,细胞因子释放综合征均为1或2级。
要点
- 45例复发/难治性Ph+ ALL患者中16例(36%;95%CI 22%至51%)在前两周期达到CR/CRh。
- 88%的CR/CRh缓解者达到完全微小残留病缓解,7例(44%)缓解者后续接受异基因造血干细胞移植。
- 中位无复发生存期6.7个月,中位总生存期7.1个月;3例发生细胞因子释放综合征(均为1或2级),3例发生3级神经系统事件。
核心结论
- 单药博纳吐单抗在TKI治疗失败后复发或难治的高危Ph+ ALL患者中显示出抗白血病活性,不良事件与既往在Ph- ALL中的经验一致。
研究设计与样本
- 开放标签II期单臂多中心研究,纳入至少一种第二代或后续TKI治疗后复发或难治、或对第二代或后续TKI不耐受且对伊马替尼不耐受或难治的Ph+ ALL成人患者。
- 博纳吐单抗以28天为周期持续静脉输注给药,主要终点为前两个周期内完全缓解(CR)或部分血液学恢复的完全缓解(CRh)。
主要发现
- 45例患者中16例(36%;95%CI 22%至51%)在前两个周期内达到CR/CRh,包括10例T315I突变患者中的4例。
- 88%的CR/CRh缓解者达到完全微小残留病缓解。
- 7例缓解者(44%)后续接受异基因造血干细胞移植,包括11例未接受过移植的缓解者中的6例(55%)。
- 中位无复发生存期6.7个月,中位总生存期7.1个月。
- 最常见不良事件为发热(58%)、发热性中性粒细胞减少(40%)和头痛(31%);3例发生细胞因子释放综合征(均为1或2级),3例发生3级神经系统事件,其中1例(失语症)需暂时中断治疗,无4级或5级神经系统事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Few therapeutic options are available for patients with Philadelphia chromosome-positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) who progress after failure of tyrosine kinase inhibitor (TKI) -based therapy. Here, we evaluated the efficacy and tolerability of blinatumomab in patients with relapsed or refractory Ph+ ALL. Patients and Methods This open-label phase II study enrolled adults with Ph+ ALL who had relapsed after or were refractory to at least one second-generation or later TKI or were intolerant to second-generation or later TKIs and intolerant or refractory to imatinib. Blinatumomab was administered in 28-day cycles by continuous intravenous infusion. The primary end point was complete remission (CR) or CR with partial hematologic recovery (CRh) during the first two cycles. Major secondary end points included minimal residual disease response, rate of allogeneic hematopoietic stem-cell transplantation, relapse-free survival, overall survival, and adverse events (AEs). Results Of 45 patients, 16 (36%; 95% CI, 22% to 51%) achieved CR/CRh during the first two cycles, including four of 10 patients with the T315I mutation; 88% of CR/CRh responders achieved a complete minimal residual disease response. Seven responders (44%) proceeded to allogeneic hematopoietic stem-cell transplantation, including 55% (six of 11) of transplantation-naïve responders. Median relapse-free survival and overall survival were 6.7 and 7.1 months, respectively. The most frequent AEs were pyrexia (58%), febrile neutropenia (40%), and headache (31%). Three patients had cytokine release syndrome (all grade 1 or 2), and three patients had grade 3 neurologic events, one of which (aphasia) required temporary treatment interruption. There were no grade 4 or 5 neurologic events. Conclusion Single-agent blinatumomab showed antileukemia activity in high-risk patients with Ph+ ALL who had relapsed or were refractory to TKIs. AEs were consistent with previous experience in Ph- ALL.
引用
- Martinelli G, Boissel N, Chevallier P, et al. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. J Clin Oncol. 2017. PMID: 28355115. doi:10.1200/JCO.2016.69.3531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。